MAM
AXSM icon

Martingale Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Martingale Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.11M Buy
12,512
+5,106
+69% +$882K 0.05% 339
2025
Q4 		$1.35M Buy
7,406
+3,606
+95% +$503K 0.03% 406
2025
Q3 		$462K Sell
3,800
-1
-0% -$113 0.01% 625
2025
Q2 		$397K Buy
+3,801
New +$402K 0.01% 652

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Martingale Asset Management's AXSM Position: Q1 2026 in Review

Martingale Asset Management increased its Axsome Therapeutics (AXSM) stake by 69% in Q1 2026, buying an estimated $882K and bringing the position to 12,512 shares worth $2.11M. The position accounts for 0.05% of the portfolio, ranked #339.

Martingale Asset Management first reported a position in AXSM in Q2 2025 and has held it in 4 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Martingale Asset Management held 12,512 shares of Axsome Therapeutics worth $2.11M as of Q1 2026.
  • Martingale Asset Management bought 5,106 Axsome Therapeutics shares in Q1 2026, an estimated $882K.
  • Axsome Therapeutics made up 0.05% of Martingale Asset Management's portfolio in Q1 2026, its #339 holding.
  • Martingale Asset Management first reported a position in Axsome Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.